Prostate Cancer

Trends in outpatient radical prostatectomy and same day discharge for prostate cancer: Analysis of the National Inpatient Sample and Nationwide Ambulatory Surgery Sample. February 7, 2025

Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial. February 7, 2025

The Value of Artificial Intelligence in Prostate-Specific Membrane Antigen Positron Emission Tomography: An Update. February 7, 2025

Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC. February 7, 2025

Targeting AXL inhibits the growth and metastasis of prostate cancer in bone. February 7, 2025

Incisional PSMA PET/CT-positive recurrences in prostate cancer- is there an implication on clinical care? February 7, 2025

Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy. February 6, 2025

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials. February 6, 2025

Refining partial gland ablation for localised prostate cancer: the FALCON project. February 6, 2025

Ultra-fast biparametric MRI in prostate cancer assessment: Diagnostic performance and image quality compared to conventional multiparametric MRI. February 6, 2025

Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer. February 6, 2025

Maintenance of patient-reported health-related quality of life post neoadjuvant relugolix prior to the initiation of prostate radiation therapy. February 5, 2025

Repeatability, reproducibility, and the effects of radiotherapy on radiomic features of lowfield MR-LINAC images of the prostate. February 5, 2025

Key Considerations for a Prostate Cancer mRNA Vaccine. February 5, 2025

Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. February 5, 2025

Molecular Landscape of Aggressive Histologic Subtypes of Localized Prostate Cancer. February 5, 2025

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate. February 4, 2025

The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials. February 4, 2025

Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer. February 4, 2025

Testosterone replacement therapy in men on active surveillance for prostate cancer. February 4, 2025

Page 1 of 1457